Perhaps the ultimate goal of medical intervention and prevention in the developed world is the extension of healthy lifespan, minimizing the maladies of aging and limiting the time during which we are incapacitated at the end of life. Scientists studying the seemingly inevitable phenomenon of aging have shown that environmental, lifestyle and genetic factors are all involved in this complex process. This new track at PMWC will probe the fundamental science of aging, the expanding arsenal of therapies to help combat the ravages of age, the costs and benefits of an extended healthy lifespan.
Genetics & Biology of Aging
Anne Brunet, Stanford
Tom Rando, Stanford
Tony Wyss-Coray, Stanford
Pankaj Kapahi, Buck Institute
Gordon Lithgow, Buck Institute
Irina Conboy, UC Berkeley
Evolution of Aging
Steven Austad, UAB
Impact of Aging on Society
Barbara Koenig, UCSF
Hank Greely, Stanford
Judith Campisi, Buck Institute
Steven Braithwaite, Alkahest, Inc
Felipe Sierra, NIH
Gerontology – Medical Aspects of Aging
John Newman, Buck Institute for Research on Aging
Meng Wang, Baylor College of Medicine
Vered Raz, Leiden University Medical Center
Andrea Maier, The University of Melbourne, Australia
Richard Allsopp, University of Hawaii
Tom Buford, University of Alabama at Birmingham
Steven Engle, CohBar
Peter Rabinovitch, University of Washington
Sandra Encalada, The Scripps Research Institute
Aubrey de Grey, SENS Research Foundation
Noah Davidsohn, Rejuvenate Bio
Matthew Hirschey, Duke University
Christian Elabd, Spring Discovery
Jeremy O'Connell, Juvena Therapeutics
Sophie Visvikis-Siest, INSERM
Polina Mamoshina, Deep Longevity
Campisi has established a broad research program to understand the relationship between aging and age-related phenotypes and pathologies, with an emphasis on the interface between cancer and aging. Her laboratory made several pioneering discoveries in these areas, and her research continues to challenge and alter existing paradigms. In recognition of her accomplishments, Campisi received numerous awards, including awards from the National Institute on Aging, AlliedSignal Corporation, Gerontological Society of America and American Federation for Aging Research, the Longevity prize from the IPSEN Foundation, and the first international Olav Thon Foundation prize in Natural Sciences and Medicine. She is an elected fellow of the American Association for the Advancement of Science and the National Academy of Science. Her current research projects include basic molecular and cell biological mechanisms of cellular senescence, aging and disease biomarker discovery and transcriptomic, proteomic and metabolomic profiling of aged and senescent cells and tissues.
Dr. Brunet obtained her B.Sc. from the Ecole Normale Supérieure in Paris and her Ph.D. from the University of Nice, France. She did her postdoctoral training with Dr. Michael Greenberg at Harvard Medical School. Dr. Brunet is interested in the molecular mechanisms of aging and longevity. She wants to understand the mechanism of neural stem cell aging. She also seeks to discover novel genes regulating longevity, notably developing a new short-lived vertebrate, the African killifish. Dr. Brunet has published over 80 peer-reviewed papers and reviews. She has received several awards, including the Pfizer/AFAR Innovation in Aging Research Award and the Vincent Cristofalo “Rising Star” Award in Aging Research. She received a Pioneer Award and a Transformative Award from the NIH Director's fund, which supports scientists who propose pioneering and transforming approaches to major challenges in biomedical research.
The African Killifish: A New Model to Understand Aging and 'Suspended Animation'
Dr. Rando’s research focuses on stem cell biology and the biology of aging. He has been a pioneer in the field of systemic factors as regulators of cellular aging beginning with seminal studies done in his laboratory using the technique of heterochronic parabiosis. These studies have formed the foundation of current approaches to epigenetic rejuvenation. He is a scientific founder of Fountain Therapeutics whose mission is to develop therapies for diseases of aging based these fundamental biological principles. Dr. Rando is Director of the Glenn Center for the Biology of Aging at Stanford and Deputy Director of the Stanford Center on Longevity. He has received numerous awards including the NIH Director’s Pioneer Award and the “Breakthroughs in Gerontology” Award from the American Federation for Aging Research. Dr. Rando is a member of the National Academy of Medicine and a Fellow of the American Association for the Advancement of Science.
A key direction of Irina Conboy laboratory is to understand age-imposed and pathological changes in signaling networks that regulate tissue maintenance and repair and to calibrate these to healthy states.Prof. Conboy received numerous awards for her work in Aging field, including Silicon Valley Foundation Award for clinical translation of aging research, Open Philanthropy Award, Packer endowment for Aging research, Raymond and Beverly Sackler TAU Award, Calico Award, Bridging the Gap, Rogers’ Award, SENS Foundation and Life Extension Foundation, W.M. Keck Foundation Award, Glenn Award for Research in Biological Mechanisms of Aging, Stem Cell Research Foundation Award, Ellison’s Medical Foundation New Scholar in Aging award, and NIH National Research Service Award.
Restoring Health And Youth To Old Tissues
We will discuss our stem cell engineering and regenerative medicine approaches that improve understanding of the determinants of homeostatic health and enable novel rational approaches to treat a number of diseases, which range from tissue degeneration to cancer and include novel ways to avoid and diminish fibrosis and inflammation. These directions have been recently ramified with synthetic biology and innovative digital biosensors for diagnostics of age-imposed alterations and for assessing the response to treatments.
Steven N Austad's early research was field-based. He has done field research in several parts of the United States, Venezuela, East Africa, Micronesia, and Papua New Guinea. Once he became interested in the biology of aging, his research became more laboratory oriented. Perhaps because of his background in English, he has always been eager to communicate the excitement of science to the public at large. In that capacity, he haswritten popular books, planned museum exhibits, and produced a regular newspaper column on science.
Prof. Koenig pioneered the use of empirical methods in the study of ethical questions in science, medicine, and health. She has long-standing interests in palliative care and technology use near the end of life. In San Francisco in the early 1980s, she was one of the first anthropologists to work on the then emerging epidemic of HIV/AIDS, focusing on the impact of the disease on clinicians’ care for dying patients. Koenig also led the first NIH-funded study of the dynamics of end-of-life decision making and patient choice in a public hospital cancer clinic serving patients from varied ethno-cultural backgrounds; her work revealed the limitations of traditional bioethics practices in a diverse society. Koenig’s research led to her being named a Soros Faculty Scholar in the Open Society Institute’s “Project on Death in America.” With the passage of California’s physician aid-in-dying legislation, she convened a state-wide conference to bring together the law’s opponents and proponents to reflect on implementation challenges.
Henry T. (Hank) Greely is the Deane F. and Kate Edelman Johnson Professor of Law and Professor, by courtesy, of Genetics at Stanford University. He specializes in ethical, legal, and social issues arising from advances in the biosciences. He directs the Stanford Center for Law and the Biosciences; chairs the California Advisory Committee on Human Stem Cell Research; serves on the NIH BRAIN Initiative’s Multi-Council Working Group, whose Neuroethics Group he co-chairs; and just ended a term as President of the International Neuroethics Society. His book, THE END OF SEX AND THE FUTURE OF HUMAN REPRODUCTION, was published in May 2016. Professor Greely graduated from Stanford in 1974 and from Yale Law School in 1977. He joined the Stanford faculty in 1985.
Steven is Chief Scientific Officer of Alkahest, developing therapeutic products for patients with age related health conditions. He also holds the position of Adjunct Associate Professor of Neurology at Rutgers University. He founded MentiNova Inc and previously led research at Circuit Therapeutics, drug discovery at Signum Biosciences, headed the cellular neurodegeneration group at Wyeth Research/Pfizer, and was a program leader at AGY Therapeutics. In these roles he has led research and development programs through multiple therapeutic modalities across a diverse range of indications in the field of neuroscience. Dr Braithwaite is a graduate of the University of Cambridge, UK, received his PhD from the University of Bristol, UK and performed postdoctoral work at Stanford University, he has published extensively in the fields of basic neuroscience research, Alzheimer’s and Parkinson’s disease.
Dr. Kapahi received his PhD from the University of Manchester, where he worked with Tom Kirkwood. He did his postdoctoral work with Seymour Benzer at Caltech and Michael Karin at University of California, San Diego. He joined the Buck Institute as an assistant professor in 2004. Dr. Kapahi has published more than 80 scientific papers and holds three current patents. He has been recognized for his scientific excellence with many awards, including the Eureka Award from the National Institute on Aging, a New Scholar Award from the Ellison Medical Foundation, a Glenn Award for Research in Biological Mechanisms of Aging, the Nathan Shock Young Investigator Award, and the Breakthrough in Gerontology and Julie Martin Mid-career awards from AFAR. He currently serves on the editorial board of Aging Cell, Aging, and PLOS Genetics. Dr. Kapahi also initiated the first master’s degree course in gerontology at the Buck Institute.
Felipe Sierra, PhD. is interested in promoting geroscience as an approach to prevent or delay all chronic diseases affecting the elderly. In addition, he is involved in developing a large NIH project on Cellular Senescence and Senolytics. He was trained as a biochemist in his native Chile and obtained a PhD in Biochemistry and Molecular Biology from the University of Florida. He has worked in Switzerland, the US, and Chile, in active research spanning academia, industry and government. In 2002, Dr. Sierra joined the Federal workforce at the NIH, and in 2006 he became Director of the Division of Aging Biology, NIA. Dr. Sierra is also the founder of the trans-NIH Geroscience Interest Group (GSIG), seeking to promote research on the geroscience hypothesis. He is currently a contractor as a Senior Advisor at NIA, as well as co-Director of the Inspire Program in Toulouse, France.
Geroscience: Let’s Focus On Health, Not Disease
Aging is at the core of our risk of developing chronic diseases. The new field of geroscience proposes that by addressing the basic biology of aging – rather than specific diseases – we will reap better results in terms of health.
A native of Scotland, Dr. Lithgow received his PhD from the University of Glasgow and obtained further training at Ciba Geigy AG in Basel, Switzerland, and at the University of Colorado. He established his lab studying the biology of aging at the University of Manchester, England, before moving it to the Buck Institute in 2000. Dr. Lithgow has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging, a senior scholarship from the Ellison Medical Foundation, and the Tenovus Award for Biomedical Research. He has served on many national advisory panels in both the United Kingdom and the United States, including the National Institute on Aging’s Board of Scientific Councilors, and has served as the chair of biological sciences at the Gerontology Society of America. Dr. Lithgow has partnered with a series of biotechnology companies in sponsored research agreements and has strong collaborations in preclinical aging research on diseases such as osteoporosis and Parkinson’s disease.
Vered Raz’s research explores molecular mechanisms regulating muscle degeneration in aging and adult-onset myopathies, with the long-term goal that this knowledge could lead to specific therapies for these conditions. The group investigates the role of mRNA processing in aging muscles combining molecular genetics with different omics approaches and molecular networks. Raz graduated at the Weizmann Institute of Science with numerous awards, among the distinguished the Israeli president award. She conducted research in three countries, and settled in the Netherlands where she is a staff member at the Human Genetics department, Leiden University Medical Centre.
The Role Of mRNA Processing In Muscle Aging
PABPN1 is a key regulator of mRNA processing. An aging-associated reduction in PABPN1 levels causes muscle wasting. Using omic research approaches the mechanisms that are predominantly affected by PABPN1 are elucidated with the focus to target molecules to therapeutic developments.
Dr. Wang’s research focuses on the molecular mechanisms governing organism longevity, reproductive fitness and lipid metabolism through harnessing the power of functional genomics, metabolomics, chemical engineering and optical biophysics. Her group discovers novel pro-longevity signaling pathways, delivers new nutraceutical targets for healthy aging, and drives technological development to investigate lipid dynamics as a function of time and space. Wang is the recipient of NIH Director’s Pioneer Award, Peter O’Donnell Award, Gibco Emerging Leader Prize and Early Career Life Scientist Award from the American Society for Cell Biology, and Glenn Award for Research in Biological Mechanism of Aging. In 2019, she was elected as a Fellow of American Association for the Advancement of Science. Wang received a B.S. in biochemistry and molecular biology from Peking University in 2001 and a Ph.D. in biomedical genetics from University of Rochester in 2005 and completed her postdoctoral training at Harvard Medical School/Massachusetts General Hospital.
Healthy Metabolism, Healthy Aging
Metabolism is fundamental to life, generating thousands of metabolites that are structural blocks, energy resources and also signaling factors. We study the novel role of metabolites in orchestrating cellular homeostasis, coordinating microbe-host communication and promoting longevity and healthy aging.
Dr. Newman is a geriatrician physician-scientist who seeks to translate our expanding understanding of aging biology to improve the care and help maintain the independence of older adults. Dr. Newman's research at the Buck Institute studies the molecular details of how diet and fasting regulate the genes and pathways that in turn control aging, focusing on the ketone body beta-hydroxybutyrate and how its molecular signaling activities involving epigenetics and inflammation affect dementia and delirium in the aging brain. Dr. Newman is also a geriatrician who cares for hospitalized older adults at UCSF and the San Francisco VA Medical Center, focusing on preserving mobility and preventing delirium. He completed an MD/PhD at the University of Washington, then residency and fellowship training at UCSF. He is an NIA Beeson Scholar.
Precision Geriatric Medicine
Precision medicine for older adults requires providing the right care at the right time that is right for the person. It spans dimensions from the molecular to the social, aligned with goals and informed by the biology of aging.
Prof. Andrea Maier graduated in Medicine at the Medical University Lübeck (Germany, 2003), registered as specialist Internal Medicine-Geriatrics (The Netherlands, 2009) and was appointed full Professor of Gerontology at the VU University Amsterdam (The Netherlands) in 2013. Since February 2016 she is Divisional Director of Medicine and Community Care at the Royal Melbourne Hospital and Professor of Medicine and Aged Care at the University of Melbourne (Australia) responsible for the daily management of non-surgical hospital and community services, and implementation of novel and (cost)-effective health care models. Her research is driven to unravel ageing mechanisms and the interaction of ageing and age-related diseases. During the last 10 years she conducted multiple European observational studies as well as clinical trials (competitive research income 19 Mio AUS$) and published more than 240 peer reviewed articles (H index 44) with her innovative, global, multidisciplinary @Age research group. She is a frequent guest in radio and television programs to disseminate ageing research and an invited member of several international academic and health policy committees (e.g. WHO).
Restoring Health After An Acute Event
Restoring health after an acute event is of major importance for health and lifespan. Physical, cognitive and biological determinants of resilience will be presented being essential to restore health.
My research focus is in the field of human longevity, specifically, the role of the FOXO3 gene on longevity, and also telomere & telomerase biology during aging and stem cell aging. I started my research in the telomere and cell senescence field in the 90s, which transitioned into a brief post-doctoral fellowship at Geron Corp (Menlo Park, CA) where I engaged in projects that initially identified and cloned the human and mouse telomerase reverse transciptase (Tert) gene. I then moved on to a post-doc position at Stanford University in the lab of Dr. Irving Weissman, where I generated and used Tert transgenic and knock-out mice to study the effect on telomeres during stem cell aging. In 2003, I joined faculty at University of Manoa to continue my research on aging, telomeres and stem cells. In 2011, I initiated a collaboration with Dr. Brad Willcox to study FOXO3 and aging in humans.
Cell & Molecular Mechanisms Of Longevity Enhancement By FOXO3
I will present our team's results on identified cell and molecular mechanisms by which the FOXO3 gene promotes human longevity.
Dr. Buford’s research spans both animal and human models and is focused on developing interventions to extend healthspan and promote independence among older adults. In particular, he has interest in optimizing the beneficial effects of physical exercise on healthy aging as well as understanding the role of the renin-angiotensin system (RAS) in preserving physical and cognitive functions. He is also a leading proponent of leveraging knowledge of the gut microbiome to improve late-life health. At UAB, Dr. Buford serves in leadership of the Nathan Shock Center on the Basic Biology of Aging as well as the UAB Center for Exercise Medicine. He is also an elected fellow of the Gerontological Society of America, the American Heart Association, and the American College of Sports Medicine. Dr. Buford he has published over 120 peer-reviewed manuscripts, served on multiple editorial boards and NIH study sections in the field of aging, and has received substantial support for his research from the National Institute on Aging.
The Renin-Angiotensin System In Healthy Aging
The renin-angiotensin system is known for blood pressure regulation, but it has other important impacts on health aging. Data from multiple species indicate potential impacts on physical/cognitive functions and interactions with skeletal muscle, and the gut microbiome, and physical exercise.
Mr. Engle joined CohBar as Chief Executive Officer in May 2019. From September 2011 until May 2019, he served as the Chief Executive Officer of Averigon Consulting, an advisory firm providing business development, fundraising, operational and consultancy services to life science companies. From August 2007 to August 2011, Mr. Engle was Chairman, Chief Executive Officer and President of XOMA Corporation (NASDAQ: XOMA), a publicly-traded biotechnology company. Previously, he held multiple executive management roles at La Jolla Pharmaceutical Company (NASDAQ: LJPC), a publicly-traded biotechnology company, including serving as Chairman and Chief Executive Officer from 1997 to 2006, President and Chief Executive Officer from 1995 to 1997, and Executive Vice President and Chief Operating Officer from 1993 to 1994. Mr. Engle currently serves as Chairman of the board of directors of Prescient Therapeutics (ASX: PTX), and as a member of the board of directors at various private companies. Mr. Engle received his B.S. in Electrical Engineering and his M.S. in Electrical Engineering from the University of Texas, Austin.
My research is focused on the role and application of short-term starvation, low calorie and/or low protein diets, so called fasting-mimicking diets, on health- and lifespan in pre-clinical to clinical studies. My scientific training is based on a background in cell biology, molecular biology, medicine, and biochemistry, all of which are highly relevant for my focus on biogerontology research to identify the mechanisms underlying cellular protection, as well as health- and lifespan-regulation, and their translation into clinical applications. I have performed research related to aging in yeast and C. elegans since 2009, shortly after which I began to utilize mouse models to study the role of growth hormone/Insulin-like growth factor 1 signaling as a major regulatory pathway that modulates lifespan and age-associated diseases/pathologies; particularly cancer.
Fasting-Mimicking Diets Induce Systemic Health Benefits
This presentation will explore the connection between aging, health, nutrition and dietary interventions. I will outline the use of fasting-mimicking diets on disease prevention, but even further how this dietary approach has wide-ranging impact on multiple aging-related diseases. Using pre-clinical research from our lab, I will then provide an outlook of which direction these studies are now moving to (incl. cancer, diabetes, ...)
The focus of Dr. Rabinovitch’s research is on the use of mouse models to examine the effects of modulating mitochondrial function on lifespan and healthspan. Transgenic mice that express catalase in mitochondria, as well as the tetrapeptide SS-31 (elamipretide) have been found to be protected against multiple health challenges, including cardiac aging and sarcopenia. His work tests the hypothesis that acute enhancement of mitochondrial function is followed by persistent structural, proteomic and metabolic remodeling that improves aged physiological performance. Studies of proteomic abundance, turnover and post-translational modification have been invaluable tools in this work. Dr. Rabinovitch is a Fellow of the AAAS, past recipient of the Denham Harmon Research Award from the American Aging Association, an Ellison Medical Foundation Senior Scholar in Aging grant award, and a Breakthroughs in Gerontology grant award from the American Federation for Aging Research.
Interventions To Enhance Aging Muscle Mitochondrial Function
Treatment with the mitochondrial targeted peptide SS-31 (elamipretide) or late-life viral expression of mitochondrial-targeted catalase (mCAT) can substantially reverse cardiac dysfunction and reduced endurance of old mice. These results implicate mitochondrial energetics and redox signaling as therapeutic targets for muscle aging.
Dr. Encalada obtained her PhD in Molecular Genetics from the University of Oregon, and did her postdoctoral training at the UC San Diego, where she was a Damon Runyon Fellow. Her research focuses on the mechanisms of intracellular transport in neurons, and the role that subcellular endocytic trafficking plays in the intracellular accumulation of misfolded proteins in the proteinopathies. By comparative modeling of Alzheimer’s Disease, prion diseases, transthyretin amyloidosis, and other tauopathies in Caenorhabditis elegans, mice, and human iPSC-derived neurons, Dr. Encalada’s lab is unvelining novel pathways that are being targeted with small molecules for development as therapies to ameliorate axonal pathologies. Her lab uses a combination of genetics, cell biology, and high-/super-resolution microscopy approaches. She has received several awards, including The Glenn Foundation Award for Research in Biological Mechanisms of Aging, The Baxter Foundation Young Faculty Award, and The Ellison Medical Foundation New Scholar in Aging Award.
Dr. Aubrey de Grey is a biomedical gerontologist based in Mountain View, California, USA, and is the figurehead of a California-based 501(c)(3) biomedical research charity that performs and funds laboratory research dedicated to combating the aging process. He is Editor-in-Chief of Rejuvenation Research, the world’s highest-impact peer-reviewed journal focused on intervention in aging. His research encompasses the characterization of all the types of self-inflicted cellular and molecular damage that constitute mammalian aging and the design of interventions to repair and/or obviate that damage. Dr. de Grey is a Fellow of the Gerontological Society of America and the American Aging Association and serves on the editorial and scientific advisory boards of numerous journals and organizations. He is a highly sought-after speaker who gives 40-50 invited talks per year at conferences, universities, companies in areas ranging from pharma to life insurance, and to the public.
Rejuvenation Biotechnology: The Medical Conquest Of Aging
Regenerative and other new medicines will eventually be so comprehensive that people will stay truly youthful however long they live. I will discuss both the biology and the sociology of what will be the most momentous advance in the history of civilization.
The Hirschey Lab studies how cells integrate nutrient sensing and metabolism. He is particularly interested in how metabolites and chemical modifications control metabolism. Metabolic regulation is important for several physiological states and disease processes, including diabetes, cardiovascular disease, cancer, and the aging process. He earned a Ph.D. in Chemistry and Biochemistry at the University of California, Santa Barbara and was a post-doctoral research fellow with Eric Verdin at the Gladstone Institutes at the University of California in San Francisco. His work has appeared in several leading journals, including Nature, Science, Cell Metabolism and Molecular Cell. He has received numerous awards including an Innovator Award from the American Heart Association, a New Scholar in Aging Award from the Ellison Medical Foundation, the Helmholtz Young Investigator in Diabetes (HeIDi) Award, and the Glenn Award. His work is currently supported by grants from the Glenn Foundation, and the National Institutes of Health.
Big Data Approaches To Identify New Targets In Aging
We present a new research tool called data-driven hypothesis (DDH) for predicting pathways and functions for thousands of genes across the human genome. We present this tool via an intuitive online interface. The DDH project holds tremendous potential to generate hypotheses, data, and knowledge in order to provide a deep understanding of the dynamic properties of mammalian genes and to identify new targets for healthy aging.
Noah Davidsohn is a co-founder and the CSO of Rejuvenate Bio, a startup out of George Church’s Lab at Harvard Medical School. Prior to Rejuvenate Bio, Noah was a Postdoctoral researcher in George Church's lab developing the underlying technology that was spun out into Rejuvenate Bio. He is also a huge animal lover whose dog inspired the work started in the Church lab. Noah has received his Ph.D. from MIT in biological engineering, M.A. from Princeton University in Electrical Engineering, and B.S. from California Institute of Technology in Applied Physics.
New Approach To Chronic Age-Related Disease And Aging
Since incorporating Juvena Therapeutics in 2017, co-Founder Dr. O’Connell has worked to build the team and technology underpinning Juvena’s unique ML-enabled drug discovery platform based on the efficient identification of lead candidates through proteomics, high-throughput screening for restored stem cell function, and validating targets in a preclinical development pipeline. Juvena Therapeutics is poised to advance optimized leads from this pipeline for several musculoskeletal indications. As CSO at Juvena Therapeutics, Dr. O'Connell guides R&D strategy and technology development. He draws on his decade of expertise in quantitative proteomics and systems biology, during which he leveraged immense proteomics datasets to build several machine learning classifiers for predicting protein-protein interactions. He has spearheaded research projects spanning departments in multiple tier one research institutions, including Harvard and Stanford, employing a combination of mass spectrometry, high throughput imaging, and computational approaches as demonstrated in his 13 publications to date, several fellowships and awards.
Translating The hESC Secretome Into Novel Biologics
Translating the hESC secretome into optimized lead molecules was accomplished by an ML-enabled discovery platform based on the efficient identification of lead candidates through proteomics, high-throughput screening for restored stem cell function, and validating targets in a preclinical development pipeline.
Sofia Siest (Sophie Visvikis-Siest), PhD, was born in Athens, Greece, where she obtained a diploma of Biology. She received a PhD on Genetic Epidemiology of Cardiovascular Diseases at the University of Nancy, France. Dr Sophie Visvikis-Siest’s main research interests are in the domain of public health, aging, personalised medicine, prevention, genetic epidemiology, genomics and pharmacogenomics, cardio-vascular diseases, VEGF and inflammation. She has published more than 330 papers in international scientific committee journals (ORCHID ID:0000-0001-8104-8425), 2 patents and has given over 100 international invited conferences. She is the President of the Santorini Conferences Association (SCs) and of the “Santorini Conferences” held every 2 years since 2002 in Santorini, Greece, in the field of Genomics, Pharmacogenomics and Personalised Medicine. The next one, The 10th Santorini Conference: SYSTEMS MEDICINE AND PERSONALISED HEALTH & THERAPY – The Odyssey from Hope to Practice: "Patient first–keep Ithaca always in your mind”, will be held from 24 to 27 Mai 2021 in Santorini (http://santoriniconference.org/).
VEGF-A, A Potential Aging Biomarker
Vascular endothelial growth factor–A (VEGF–A) is implicated in angiogenesis, lymphangiogenesis, vascular permeability, and haematopoiesis. It is associated with numerous age-related pathologies including cardio-vascular diseases and several types of cancer. A high heritability of this trait, 60%, was estimated in the STANISLAS cohort. Consequently, we searched, by a Genome Wide Association Study (GWAS), the VEGF–A genetic variants and the inter-connexions of these biomarkers with other aging disease-associated molecules in healthy populations. Ten polymorphisms explaining more than 50% of VEGF–A heritability were identified. These variants, directly or via gene x gene x environment interactions had significant effects on HDL, LDL, TNF-a, IL-6, E selectin and ICAM-1 plasma levels. Ongoing investigations focus on clinical implementation of the ‘–omics’ determinants of this biomarker.
Dr. Mamoshina’s main focus includes computational biomarkers. She was leading the applied artificial intelligence in biomarker discovery as a Head of Biomarker Development at Insilico Medicine Hong Kong. When Insilico Medicine decided to spin-off biomarker research, Dr. Mamoshina joined Deep Longevity. Dr. Mamoshina launched Young.AI, a digital platform that integrated multiple biomarkers of aging. She published over 20 peer-reviewed publications in the area of longevity and machine learning, and first author of seminal papers on deep learned biomarkers of aging, co-author of ‘Biomarkers of Human Aging’ book (Springer, 2020). Dr. Mamoshina holds a bachelor’s degree in Genetics from Moscow State University and a Ph.D. in Computer Science from the University of Oxford.
Deep Aging Clocks
Developing human longevity therapies is rather challenging. Application of accessible biomarkers of aging can help us to speed up this process and also allow the translation of desired interventions into the clinic.